ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

Among patients with muscle-invasive bladder cancer, ctDNA-guided adjuvant therapy with atezolizumab led to significantly longer disease-free survival and overall survival than placebo. (Funded by F. Hoffmann-La Roche; IMvigor011 ClinicalTrials.gov number, NCT04660344.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-10-20
DOI
https://doi.org/10.1056/nejmoa2511885
Citations
47
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
94.30
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

Ja Hyeon Ku, Marine Gross‐Goupil, Òscar Reig, Daniel Castellano et al.
47 citations
New England Journal of Medicine
Bladder and Urothelial Cancer Treatments
94.30
article

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

Ja Hyeon Ku, Marine Gross‐Goupil, Òscar Reig, Daniel Castellano, Łukasz Dołowy, Marco Maruzzo, Giampaolo Tortora, Se Hoon Park, Zoe J. Assaf, Sergio Bracarda, Jae‐Lyun Lee, Yüksel Ürün, Jürgen E. Gschwend, Ariel Galapo Kann, Rafael Morales‐Barrera, Hiroyuki Nishiyama, Joaquim Bellmunt, Lydia Makaroff, F. Pontes Grando, Jacqueline Vuky, Viraj Degaonkar, Andrea Necchi, Emilio Francesco Giunta, Wei Zou, Elizabeth E. Steinberg, Thomas B. Powles, Álvaro Pinto, Jørgen Bjerggaard Jensen, Di̇lek Erdem, Dingwei Ye, Shusuan Jiang
article en
47 citations

Abstract

Among patients with muscle-invasive bladder cancer, ctDNA-guided adjuvant therapy with atezolizumab led to significantly longer disease-free survival and overall survival than placebo. (Funded by F. Hoffmann-La Roche; IMvigor011 ClinicalTrials.gov number, NCT04660344.).

New England Journal of MedicineVol. 393(24)
Università Cattolica del Sacro Cuore (IT), Ulsan College (KR), Hebron University (PS), University of Tsukuba (JP), Ankara University (TR), Université de Bordeaux (FR), Vita-Salute San Raffaele University (IT), Queen Mary University of London (GB), Aarhus University (DK), Hospital Universitario La Paz (ES), Asan Medical Center (KR), Samsung Medical Center (KR), Agostino Gemelli University Polyclinic (IT), Seoul National University Hospital (KR), University of Ulsan (KR), Fudan University Shanghai Cancer Center (CN), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Hospital Alemão Oswaldo Cruz (BR), Hospital Universitario 12 De Octubre (ES), Mylan (South Africa) (ZA), Istituto Oncologico Veneto (IT), Hunan Cancer Hospital (CN), Dana-Farber Cancer Institute (US), Istinye University (TR), Azienda Ospedaliera S.Maria (IT), IRCCS Ospedale San Raffaele (IT), Dana-Farber/Harvard Cancer Center (US), Central Clinical Hospital (PL), Bladder Cancer Advocacy Network (US), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Centro de Pesquisas Oncológicas (BR), Vall d'Hebron Institute of Oncology (ES), Sungkyunkwan University (KR)
Openalex Percentile: Top 0%
Bladder and Urothelial Cancer Treatments
94.30
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.